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this study, but we decided to leave them
out to enhance the reliability of the results.
As mentioned in the article, this
study is a retrospective study, due to
which it has limitations.1 We tried to im-
prove the data homogeneity, however, by
applying strict inclusion criteria as much
as we could to overcome the effect of
differences in the treatments between the
past and the present.
The main topic of our article was
the necessity of adjuvant radiation therapy
in the completely resected invasive thy-
moma, including stages II and III thy-
moma. Furthermore, unlike in the study of
Venuta et al, we did not cover thymic
carcinoma and incompletely resected tu-
mors in the study.2 It would be difficult to
compare our article with the article on the
results of the study by Venuta et al. because
the characteristics of the tumor are very
different. It is well known that in an
inoperable thymoma or thymic carci-
noma, chemotherapy might be needed in
the neoadjuvant/adjuvant setting. However,
both were not the objects of this study.
Therefore, it was not important to mention
chemotherapy. Moreover, it is difficult to
tell the relationship between chemother-
apy and its absence after metachronous
cancer, and the outcome of invasive thy-
moma, because there are various differ-
ences between the patients (Table 1).
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A Practical Guide to
Measure “All”
Malignant Pleural
Mesothelioma Tumors
by Modified RECIST
Criteria?
To the Editor:
We read with interest the practical
guidelines offered by Tsao et al.1 on
how to make measurements of malig-
nant pleural mesothelioma (MPM) by
modified RECIST criteria. When we
try to make a diagnosis of MPM, we
usually rely on a combination of clin-
ical characteristics, of radiological and
(more recently also) nuclear imaging
findings together with a confirmatory
pleural biopsy and/or pleural cytology
sample.2 Careful measuring of MPM
tumor on computed tomography (CT)
scan of the chest is crucial not only at
initial diagnosis and staging but also
for correct identification of tumor
response to treatment. MPM may,
however, present not only as a well-
delineated and measurable pleural
thickening but sometimes also as a
much thinner, not really well-delin-
eated rind-like pleural involvement.
Occasionally, pleural involvement by
MPM is only macroscopically detect-
able during thoracoscopy and later
microscopically proven while the CT
imaging does not show any significant
pleural thickening at all. Differential
diagnosis between minimal benign
pleural thickening and MPM can in-
deed prove to be very challenging
based on CT scan only, and recently,
the additional value of the fluorode-
oxyglucose positron emission tomog-
raphy imaging combined with CT scan
has been demonstrated.2
What we actually missed in this
practical guideline by Tsao et al. were
the tips to “evaluate” MPM cases with
these radiologically minimal rind-like
thickenings or with occasional “non-
measurable” or “normal” pleural MPM
disease. When we participated in the
landmark MPM trial by Vogelzang et
al.,3 measurements of MPM pleural
involvement were uniformly per-
formed using the study protocol effi-
cacy criteria for tumor response as
modified from the preexisting South-
west Oncology Group standard tumor
response criteria published by Green
et al.4 Briefly, in patients with unidi-
mensionally measurable disease,
thickness of pleural rind had to be
measured at three separate levels on
transverse CT cuts. Levels should be
at least 2 cm apart from each other. At
each level, measurement of up to three
areas of pleural rind should be per-
formed where feasible. Measures
should not be made of pleural thicken-
ing that was less than 1 cm. If
bidimensionally measurable lesions
coexisted, these could be measured ac-
cording to RECIST criteria and the
measurements could be added to the
sum of the unidimensional measure-
ments. In 2004, these adapted or mod-
ified RECIST guidelines on how to
measure MPM tumors were published
in detail by Byrne et al.5
According to the Vogelzang trial
protocol, MPM disease status could be
defined not only as measurable disease
but sometimes also as “non-measurable”
or “evaluable” disease and rarely as
“nonevaluable” disease. Evaluable
disease was defined as pleural lesions
on CT scan with perpendicular diam-
eters smaller than 1.0 cm, as has been
also detailed in the practical guidelines
by Tsao et al.1 In this category of
evaluable or non-measurable rind-like
pleural thickenings also pleural thick-
ening secondary to previous talc
pleurodesis may be classified. It is
important, however, to document
evaluable MPM disease at baseline
and during treatment, because the evo-
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lution of both measurable and evalu-
able disease needs to be taken into
account for future response definition.4
This also holds partly true for non-
evaluable MPM disease (like pleural
effusion or ascites) because, for objec-
tive complete tumor response, non-
evaluable MPM disease needs to be
completely absent. In MPM patients
with nonevaluable disease only where
no complete response is present, no
other MPM disease status can be as-
sessed.
As a suggestion, therefore, and
in expectation of possible newer eval-
uation tools for MPM,2 we would like
to propose the authors to provide cli-
nicians with a complete practical
guide on how to make radiologic mea-
surements and evaluations of all pos-
sible MPM cases, presenting mostly
with measurable, sometimes non-measur-
able, and occasionally with evaluable-only
pleural disease.
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Reply to the Letter to
the Editor Entitled A
Practical Guide to
Measure “All”
Malignant Pleural
Mesothelioma Tumors
by Modified RECIST
Criteria?
In Reply:
We fully agree with Nackaerts et
al. that there are significant radio-
graphic challenges encountered when
measuring thoracic mesothelioma tu-
mors. As pointed out, mesothelioma is
not always measurable by computed
tomography (CT), magnetic resonance
imaging, or positron emission tomog-
raphy (PET) scans, and the classifica-
tion of “nonmeasurable but evaluable”
is a common conundrum. However,
given our limitations with cost, tech-
nology availability, and consistency in
radiographic measurements, the stan-
dard of care in cooperative group trials
is to measure thoracic mesothelioma
tumors with serial CT scans. Modified
RECIST criteria by Byrne and Nowak1
is the preferred method of evaluating pleu-
ral tumors on CT scans as pleural disease
measurements, using the short-axis rather
than the long-axis diameter, appear to cor-
relate better with clinical outcome.
Given the rare incidence of mesothe-
lioma and occasional confusion on
how to measure pleural rinds, the in-
tent of our recent publication2 was to
serve as a practical guide (a step-by-
step manual) to enhance consistency in
disease measure-ments for the South-
west Oncology Group institutions.
We concur with Nackaerts et al.
that our current measurement practice is
not optimal, and future studies of tech-
nology are vital to develop better and
more consistent measurements. In our
recent publication, we did not intend to
write a review on the different imaging
modalities of measuring mesothelioma,
which was clearly summarized in the
recent publication by Nowak et al.3 The
dilemma of measuring the “nonmeasur-
able but evaluable” mesothelioma
tumors is that there is currently no tech-
nology that has been validated or con-
sistently accurate. The labor-intensive
strategy of area measurements rather
than linear measurements would be im-
practical for a cooperative group to un-
dertake, as not all investigators would
have the resources, time, or expertise to
conduct this study. While fluorodeoxy-
glucose PET and PET-CT scans are
gaining popularity in imaging mesothe-
lioma, and does show some promise,
there are multiple factors that cause
standardized uptake value measure-
ments to vary from the initial baseline
study to subsequent serial studies; and
there is neither consensus nor validation
of response criteria for mesothelioma.
Some studies4–6 have previously re-
ported a correlation to clinical outcome
using either a metabolic response by
measuring maximum standardized up-
take values or total glycolytic volume;
however, these trials are small in num-
ber and other studies7,8 have reported
conflicting results. It is clear that addi-
tional prospective trials with radio-
graphic correlates are needed to validate
and develop new strategies based on our
current technical capabilities; we hope
that future research, perhaps new novel
PET tracers, will overcome the com-
plexity of measuring this nonspherical
tumor.
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